Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Device for Cell Culturing, Monitoring and Containment Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before April 24, 2006 will be considered.
View Prospective Grant of Exclusive License: Food Quality Indicator Device Only written comments and/or application for a license which are received by the National Institutes of Health on or before April 10, 2006 will be considered.
View Prospective Grant of Exclusive License: Aminoflavone Compounds as Anti-Cancer Agents Only written comments and/or license applications which are received by the National Institutes of Health on or before April 10, 2006 will be considered.
View Prospective Grant of an Exclusive License: “Vasostatin as Marrow Protectant” and “Use of Calreticulin and Calreticulin Fragments To Inhibit Endothelial Cell Growth and Angiogenesis and Suppress Tumor Growth” Only written comments and/or license applications which are received by the National Institutes of Health on or before April 3, 2006 will be considered.
View Prospective Grant of Exclusive License: FDA Approvable Human DNA Diagnostic Test for Endometriosis Only written comments and/or application for a license which are received by the National Institutes of Health on or before April 3, 2006 will be considered.
View Prospective Grant of Exclusive License: FDA Approvable Human Diagnostic for Osteoarthritis Only written comments and/or application for a license which is received by the NIH Office of Technology Transfer on or before March 21, 2006 will be considered.
View Prospective Grant of Exclusive License: Anthrax Lethal Factor Is a MAPK Kinase Protease Only license applications which are received by the National Institutes of Health on or before March 13, 2006 will be considered.
View Prospective Grant of Exclusive License: Software for Predicting Molecular Properties and Pathogen Detection Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before February 28, 2006 will be considered.
View Prospective Grant of Exclusive License: Treatment of Cardiovascular Conditions With Nitrite Therapy Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before February 28, 2006 will be considered.
View Prospective Grant of Exclusive License: Fusion Proteins Comprising Circularly Permuted Ligands Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 28, 2006 will be considered.
View Prospective Grant of Exclusive License: Implants for Sustained Ocular Therapeutic Agent Delivery Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before February 28, 2006 will be considered.
View Prospective Grant of Exclusive License: Cleaning Mucus From Endotracheal Tubes Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before January 9, 2006 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: North-2'-Deoxy-Methanocarbathmydines as Antiviral Agents Against Poxvirus Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before December 6, 2005 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Development and Use of Cripto-1 as a Biomarker and Treatment for Neurodegenerative Disease Only written comments and/or applications for a license, which are received by the NIH Office of Technology Transfer on or before October 4, 2005 will be considered.
View Prospective Grant of an Exclusive License: Therapeutics for the Treatment of Kidney Cancer and Thyroid Neoplasms Only written comments and/or license applications which are received by the National Institutes of Health on or before October 3, 2005 will be considered.
View Prospective Grant of Exclusive License: Adaphostin as a Novel Cancer Therapy Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 3, 2005 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of an Exclusive License: Anti-Cancer Vaccines Only written comments and/or license applications which are received by the National Institutes of Health on or before October 3, 2005 will be considered.
View Prospective Grant of Exclusive License: Treatment of Inflammatory Diseases Using Ghrelin Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before October 3, 2005 will be considered.
View Prospective Grant of Exclusive License: Use of HIV-Dependent Expression Constructs and Uses Therefor for the Development of FDA-Approvable HIV Diagnostic Kits Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before September 20, 2005 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing and Cooperative Research and Development Agreement (CRADA): Aminoflavone Prodrug
View Prospective Grant of Exclusive License: Mesothelin, a Differentiation Antigen Present on Mesothelium, Mesotheliomas and Ovarian Cancers and Methods and Kits for Targeting Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 12, 2005 will be considered.